Mizzou Specialty Pharmacy


Background

. Palivizumab is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients.^[1]

. Due to the high cost, handling requirements, administration route, and importance of adherence, palivizumab is best managed by specialty pharmacies able to provide robust clinical services.


. In collaboration with the health system and surrounding pediatric clinics, a specialty pharmacy management program was established to serve patients receiving palivizumab.


. This program was unique because it required a health system specialty pharmacy to form a relationship with a privately owned clinic in the community.



Development of a Palivizumab Specialty Pharmacy Management Program

Authors: Lana Harlan, RPh; Carrie Gatzke, PharmD, CSP; Alexandra Majors, PharmD, BCACP, CSP; Katlyn Benskin, CPhT





R	e	S
Γ	C	3

201

- **Referrals** Received
- **APPROVED PRIOR AUTHORIZATION**
- TRIAGED TO OUTSIDE SPECIALTY PHARMACY
- MANAGED BY MIZZOU SPECIALTY PHARMACY
- PATIENTS DID NOT PURSUE
- **DENIED PRIOR AUTHORIZATION**
- **APPROVED FOR PATIENT ASSISTANCE**
- HOSPITALIZATIONS FROM RSV


sults

52017	2017—2018	2018—2019	Total
55	72	112	239
50	39	83	172
9	6	19	34
34	36	59	129
6	7	5	18
7	10	31	48
7	8	4	19
2	1	1	4
			-

Health Care



- . Mizzou Specialty Pharmacy successfully developed relationships with local pediatric clinics to serve their patients receiving palivizumab.
- . Management by Mizzou Specialty Pharmacy played a role in medication adherence and decreased RSV hospitalizations.
- . Results indicate a need to expand our services to additional providers in the community.



Reference: ^[1]Synagis (palivizumab) [prescribing information] Gaithersburg, MD: MedImmune LLC; May 2019